UB Paderborn / Katalog / Suche / in CDI

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

Blood, 2013-05, Vol.121 (20), p.4046-4055

2013

Link zum Volltext

Verfügbarkeit prüfen

Pain and pain management in haemophilia

Blood coagulation & fibrinolysis, 2016-12, Vol.27 (8), p.845-854

2016

Link zum Volltext

Verfügbarkeit prüfen

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment

British journal of haematology, 2017-10, Vol.179 (2), p.298-307

2017

Link zum Volltext

Verfügbarkeit prüfen

Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation – the surgical STER

British journal of haematology, 2011-02, Vol.152 (3), p.340-346

2011

Link zum Volltext

Verfügbarkeit prüfen

Outcome measures for adult and pediatric hemophilia patients with inhibitors

European journal of haematology, 2017-08, Vol.99 (2), p.103-111

2017

Link zum Volltext

Verfügbarkeit prüfen

The case for wider use of recombinant factor VIII concentrates

Critical reviews in oncology/hematology, 2012-07, Vol.83 (1), p.11-20

2012

Link zum Volltext

Verfügbarkeit prüfen

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

Blood, 2016-04, Vol.127 (14), p.1761-1769

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical phenotypes and factor VII genotype in congenital factor VII deficiency

Thrombosis and haemostasis, 2005-03, Vol.93 (3), p.481

2005

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management

Blood transfusion = Trasfusione del sangue, 2018-11, Vol.16 (6), p.535-544

2018

Link zum Volltext

Verfügbarkeit prüfen

Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-05, Vol.27 (3), p.340-350

2021

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience

Thrombosis research, 2014-11, Vol.134, p.S27-S32

2014

Link zum Volltext

Verfügbarkeit prüfen

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study

Blood, 2007-06, Vol.109 (11), p.4693-4697

2007

Link zum Volltext

Verfügbarkeit prüfen

Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors

Thrombosis and haemostasis, 2016-04, Vol.115 (4), p.729

2016

Link zum Volltext

Verfügbarkeit prüfen

Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation

Thrombosis and haemostasis, 2013-02, Vol.109 (2), p.238

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-05, Vol.22 (3), p.419-425

2016

Link zum Volltext

Verfügbarkeit prüfen

Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice

European journal of haematology, 2012-05, Vol.88 (5), p.371-379

2012

Link zum Volltext

Verfügbarkeit prüfen

Prospective study of continuous infusion with Beriate® P in patients with severe haemophilia A undergoing surgery – a subgroup analysis

Thrombosis research, 2014-11, Vol.134, p.S43-S47

2014

Link zum Volltext

Verfügbarkeit prüfen

Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future

Blood transfusion = Trasfusione del sangue, 2014-07, Vol.12 (3), p.314-319

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-05, Vol.22 (3), p.426-432

2016

Link zum Volltext

Verfügbarkeit prüfen

Rationale for individualizing haemophilia care

Blood coagulation & fibrinolysis, 2015-12, Vol.26 (8), p.849-857

2015

Link zum Volltext

Verfügbarkeit prüfen

Switching treatments in haemophilia: is there a risk of inhibitor development?

European journal of haematology, 2015-04, Vol.94 (4), p.284-289

2015

Link zum Volltext

Verfügbarkeit prüfen

Haemate® P/Humate-P® for the treatment of von Willebrand disease: considerations for use and clinical experience

Haemophilia : the official journal of the World Federation of Hemophilia, 2008-11, Vol.14 (s5), p.39-46

2008

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect

Thrombosis and haemostasis, 2014, Vol.112 (2), p.424

2014

Link zum Volltext

Verfügbarkeit prüfen

Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?

Thrombosis research, 2014-06, Vol.133 (6), p.967-971

2014

Link zum Volltext

Verfügbarkeit prüfen

Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors

Blood transfusion = Trasfusione del sangue, 2017-01, Vol.15 (1), p.77-84

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study

Pain and pain management in haemophilia

Intracranial haemorrhage in children and adolescents with severe haemophilia A or B – the impact of prophylactic treatment

Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation – the surgical STER

Outcome measures for adult and pediatric hemophilia patients with inhibitors

The case for wider use of recombinant factor VIII concentrates

Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial

Clinical phenotypes and factor VII genotype in congenital factor VII deficiency

Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management

Practical considerations for nonfactor‐replacement therapies in the treatment of haemophilia with inhibitors

Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience

Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study

Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors

Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation

Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency

Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice

Prospective study of continuous infusion with Beriate® P in patients with severe haemophilia A undergoing surgery – a subgroup analysis

Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future

Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency

Rationale for individualizing haemophilia care

Switching treatments in haemophilia: is there a risk of inhibitor development?

Haemate® P/Humate-P® for the treatment of von Willebrand disease: considerations for use and clinical experience

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect

Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?

Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors

Suchergebnisse filtern